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Abstract
Available avian influenza (AIV) serological diagnostic tests cannot distinguish vaccinated from naturally infected birds.
Differentiation of vaccinated from infected animals (DIVA) is currently advocated as a means of achieving the full control of
H5N1. In this study, for the first time, recombinant ectodomain of M2 protein (M2e) of avian influenza virus (H5N1 strain)
was used for the DIVA serology test. M2e was cloned into pMAL-P4X vector and expressed in E. coli cells. We used Western
blot to recognize the expressed M2e-MBP protein by chicken antisera produced against live H5N1 virus. Also, the specificity
of M2e-MBP protein was compared to the M2e synthetic peptide via ELISA. In M2e-MBP ELISA, all sera raised against the live
avian influenza viruses were positive for M2e antibodies, whereas sera from killed virus vaccination were negative.
Furthermore, M2e-MBP ELISA of the field sera obtained from vaccinated and non-vaccinated chickens showed negative
results, while challenged vaccinated chickens demonstrated strong positive reactions. H5N1-originated recombinant M2e
protein induced broad-spectrum response and successfully reacted with antibodies against other AIV strains such as H5N2,
H9N2, H7N7, and H11N6. The application of the recombinant protein instead of synthetic peptide has the advantages of
continues access to an inexpensive reagent for performing a large scale screening. Moreover, recombinant proteins provide
the possibility of testing the DIVA results with an additional technique such a Western blotting which is not possible in the
case of synthetic proteins. All together, the results of the present investigation show that recombinant M2e-MBP can be
used as a robust and inexpensive solution for DIVA test.
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Introduction
Highly pathogenic avian influenza virus (AIV) of H5N1 subtype
has become endemic in poultry in some countries, especially in
Southeast Asian Countries [1]. The continuous presence of H5N1
in the environment has considerable veterinary and social
consequences. Due to devastating losses of H5N1 in most poultry,
life-long vaccination of commercial poultry has become a necessity
[2,3,4]. H5N1 is also a zoonotic agent which has caused human
death in number of countries through direct contact of human
with infected poultry [5,6]. Therefore, in the context of both
veterinary and social standpoints, it is important to reduce the
level of H5N1 in the environment [7].
Multiple vaccinations are expensive and in many instances not
entirely effective enabling H5N1 to persist in the environment and
mutate through the process known as ‘‘antigenic drift’’ [4,8].
Surveillance of vaccinated poultry for H5N1 that is, differentiation
of vaccinated from infected animals (DIVA), is advocated as a
mean to achieve the full control of H5N1, leading to eventual
eradication [9,10]. The main issue is that the common available
diagnostic tests can not differentiate vaccinated from naturally
infected birds.
To overcome this limitation, several DIVA strategies have been
attempted; the most feasible approach is the use of subunit-based
strategy which targets differential rate of propagated avian
influenza proteins between killed virus (vaccine) and naturally
infected birds. Hemagglutinin (H) is the most used target subunits
[11]. HA allows serologic surveillance in both infected and
vaccinated birds. However, the major drawback of HA-based
strategy is the high number of HA molecules per virion (500)
giving positive result in infected and vaccinated birds. In addition,
influenza virus evades humoral immune response by rapid
mutation of HA and NA coat proteins (HA and NA) [12].
A major improvement was the use of nonstructural protein 1
(NS1) as the target subunit which has zero copy number per
mature virion [13]. Infected host cells contain large quantities of
this protein, but NS1 does not package in virion [13]. As a result, a
DIVA test based on differential antibody response to NS1 protein
can differentiate infected from vaccinated birds [11]. However, it
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has been shown that the accuracy of NS1-based DIVA test
decreases by the time and produces non-specific reactions [13].
Another surface segment of influenza virus, the matrix protein 2
(M2), is a transmembrane integral protein where it exists as
homotetramer, each monomer contains 96 amino acid with 3
domains: a small external domain (M2e) comprising 23 amino
acids, a transmembrane domain (19 amino acids) and a
cytoplasmic domain (54 amino acid) [14,15].
The matrix protein 2 (M2) is receiving increased attention since
unlike HA and NA, the extracellular domain of the M2 protein
(M2e) is not subjected to severe immune selection pressure and is
very well conserved [12]. Vaccinated mice with M2e protein
showed complete protection against challenges with highly
pathogenic (homologous and heterologous) human influenza
[16,17]. Indeed, M2 protein revealed a high potential as a vaccine
for prevention of swine influenza virus disease [18]. In spite of its
high potential, there is no report on application of M2e as vaccine
in poultry.
The extracellular domain of the M2 protein (M2e protein) is
abundantly expressed on the surface of infected cells, while it is
present in small quantities in the mature virions (20–60 molecules
per vision) [19,20]. Hence, humans/animals vaccinated with
conventional inactivated influenza vaccines are not expected to
have M2e-binding antibodies [21].
Only a limited number of studies have examined M2e as a
diagnostic marker in DIVA test. Lambrecht, et al. (2007) and Kim
et al (2010) utilized the M2e synthetic peptide in ELISA and were
successful in discrimination of infected and vaccinated birds
indicating the potential of M2e for DIVA test [22,23]. This
approach (synthetic peptide-based ELISA) requires a large amount
of synthetic peptide, which is expensive for routine flock
monitoring [24] and restricts its application. Another shortcoming
of the synthetic peptide is that the result of ELISA in doubtful
samples cannot be examined by another serological method such
as Western blotting. The mentioned limitations might be
overcome by production of M2e recombinant protein in a highly
efficient platform such as E.coli and utilizing DIVA test based on
the recombinant protein.
In the present study, the M2e from a H5N1 Indonesian strain
expressed in E. coli as a recombinant protein and evaluated by
ELISA for its ability to detect antibodies to M2e antigen in
reference antisera and in chicks infected or vaccinated with
different subtypes of AIV. This study provides an efficient and
affordable method for differentiation of vaccinated from naturally
infected chicken which is an industrial demand.
Materials and Methods
Synthesis of the Me2 Gene Construct
We selected consensus open reading frame of the M2e domain
of M2 protein based on the multiple alignment of available H5N1
sequences of H5N1 Indonesian strains in GeneBank (http://www.
ncbi.nlm.nih.gov/). Selected sequence had the first 72 nucleotides
of M2 mRNA of A/Indonesia/CDC540/2006 strain (accession
number EU014132.1). The obtained sequence was optimized for
the expression in E. coli since the wild-type M2e gene contained
rare codons with a considerable frequency and several negatively
cis-acting motifs, which might hamper its expression in E. coli. The
optimised gene was synthesized, cloned into NT1 cloning vector
with Bam HI and Sal I restriction sites at the 59 and 39 ends of the
gene, respectively. The correct orientation of the M2e open
reading frame was confirmed by sequencing (GENEART AG;
Gewerbpark- Regensburg, Germany; www.geneart.com).
Cloning and Expression of the M2e Recombinant Protein
M2-NT1 vector was transformed into BL21 strain of E. coli
according to Sambrook and Russell protocol [25]. After amplifi-
cation, the plasmid was isolated, then digested using restriction
enzymes Bam HI and Sal I (New England Biolabs. Inc, Ipswich,
MA, USA), and ligated into pMAL-P4X expression vector (New
England Biolabs. Inc, Ipswich, MA, USA). This expression vector
carried maltose binding protein (MBP) as a fusion protein for
further purification. Finally, the recombinant vector of M2e-
pMAL was constructed. The M2e-pMAL expression vector was
transformed into E. coli, BL21 cells using electroporation method.
Then, the grown colonies were verified to contain M2e-pMAL by
PCR and sequencing in both directions.
For expression of recombinant M2e-MBP protein, a single
colony of transformed BL21 cells was cultured in a rich Luria-
Bertani Medium (LB) (10 g Tryptone, 10 g NaCl, 5 g yeast
extract and 0.1% D-glucose per liter of distilled water)
containing 30 mg/ml of filtered sterile Ampicillin. The 10 ml
overnight culture was transferred in 1 L of LB medium
containing Ampicillin and incubated at 37uC until optical
density at 600 nm (OD600) reached to about 0.5, then the
production of M2e-pMAL protein was induced by application
of 0.3 mM isopropyl b-D-1-thiogalactopyranoside (IPTG) (Sig-
ma, St Louis, MO, USA) with subsequent incubation for 3 h at
250 rpm at 37uC. A non-induced culture was used as a negative
control. The culture fluid was centrifuged at 5,0006g for
20 min at 4uC in (Sorvall RC 5B centrifuge). The supernatant
was discarded, and the cells were resuspended in 400 ml Tris/
sucrose buffer (30 mM Tris-HCl, 20% sucrose, 1 mM EDTA,
pH 8.0). Then, the suspension incubated for 5–10 minutes at
room temperature with shaking, or stirring, and centrifuged at
80006g at 4uC for 10 minutes. The pelleted cells were
resuspended in 400 ml ice-cold 5 mM MgSO4, incubated for
10 minutes in an ice-water bath and centrifuged as mentioned
above. The supernatant was termed ‘‘cold osmotic shock fluid’’.
Purification of M2e-MBP Fusion Recombinant Protein
The ‘‘cold osmotic shock fluid’’ containing M2e-MBP loaded
onto a column of amylose affinity resin (New England Biolabs,
Beverly, Mass., USA), washed overnight at 4uC with 5 volumes of
column buffer (20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA,
1 mM NaN3 and 1 mM Dithiothreitol). Then, the M2e-MBP
protein eluted with column buffer containing 10 mM maltose
(Sigma, St Louis, MO, USA). The first 10 fractions were collected
and protein concentration of each fraction monitored by
measurement of OD280 on a NanoDrop system (Thermo
Scientific, DE, USA). The fractions that contained measurable
protein were desalted and concentrated by ultrafiltration in
Vivaspin size exclusion centrifugal membrane tube with cut-off
30,000 Dalton (Sartorius Stedim Biotech, Goettingen Germany).
Protein concentration of the purified protein was measured using
NanoDrop, adjusted at 800 mg/ml and stored in aliquots at
270uC.
Analysing of Purified Protein by SDS-PAGE
Purified protein was analysed by sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) using gels with 12.5%
concentration of acrylamide. Pre-stained molecular weight mark-
ers (New England Biolabs. Inc, Ipswich, MA, USA) and purified
MBP protein (previously purified) were included as standards.
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Western Blotting
Purified recombinant M2e-MBP protein was ran on 12.5%
SDS-PAGE and transferred to a nitrocellulose membrane.
Molecular weight markers (New England Biolabs, Beverly, Mass,
USA) were also included. After transferring, the membrane was
blocked using 10% bovine serum albumen (BSA) in PBS
containing 0.5% Tween 20 for 2 h at room temperature. Test
sera (Table 1) were diluted 1:500 in dilution buffer (PBS- Tween
containing 1% BSA) and incubated for 1 h. The membrane was
probed for 1 h at room temperature with a rabbit anti-chicken
IgG conjugated to horse-radish peroxidase (Millipore, Temecula,
California, USA). After washing with PBST, protein bands were
visualized using diaminobenzidine (DAB) (Sigma-Aldrich Pty. Ltd)
as substrate.
Synthetic Peptides
Two synthetic peptides corresponding to the M2e recombinant
sequences were made; the M2e-23 peptide, corresponding to
amino acid position 2 to 24, with the sequence SLLTEVETPTR-
NEWECKCSDSSD, and the M2e-18 peptide, amino acid
position 2 to 18, with the sequence SLLTEVETPTRNEWECKC.
Both peptides were synthesized by PEPTIDE 2.0 (Chantilly, VA,
USA) with a minimum of 85% purity as measured by high
performance liquid chromatography. Both peptides had high
solubility in distilled water.
Reference AIV Antisera
Antisera against different strains and subtypes of AIV were
obtained from the Veterinary Laboratory Agency (New Haw,
Addlestone, UK) and CSIRO Australian Animal Health Labora-
tory, Geelong, Victoria (Table 1). All sera were produced in
specific pathogen-free (SPF) chicks by inoculation of either
inactivated AIV only (as a source of vaccine antibodies), or by
inoculation of inactivated AIV followed by challenge with live AIV
of the same H and N subtype two weeks after each immunization
(as a source of challenged antibodies). In all of the cases, the SPF
chicks were immunized twice with the inactivated virus and then
inoculated with live virus only in challenged groups. Haemagglu-
tination inhibition (HI) titers were determined in each serum by
the suppliers using the homologues antigen similar to the one used
for immunization.
Optimization of Recombinant M2e-MBP ELISA
A checkerboard titration of the M2e-MBP antigen and AIV
positive and negative sera were initially performed to determine
the optimal OD at 450 nm (OD450) of each positive and negative
serum. Briefly, purified M2e-MBP protein, diluted in 0.1 M
carbonate– bicarbonate buffer (pH 9.6), at concentrations of 200
to 0.82 mg/ml, was used to coat the 96-well flat bottom microtitre
plate (Sarstedt, Nu¨mbrecht, Germany). The coated plates were
incubated at room temperature (RT) overnight and then washed
three times with high salt wash buffer (WB), (NaCl, 37.5 g, KCl,
0.2 g, Na2HPO4, 1.15 g, KH2PO4, 0.5 g, Tween 20, 0.5 ml in
1 L distilled water, pH 7.2). The unsaturated sites were blocked by
5% BSA in PBS (200 ml/well) at RT for 2 h, and subsequently
washed three times with WB. Test sera were diluted 1:25 to 1:800
in dilution buffer (DB) (0.1 M Tris pH 7.4, 0.5 M NaCl, 1 mM
Na2EDTA, 2% w/v BSA, 3% w/v Triton X-100, 3% w/v Tween
20) and added (100 ml/well) in duplicate to the wells and
incubated at RT for 1 h. Positive and negative controls were
included in all assays in quadruplicate. The plates were washed
three times with PBS-T. Horseradish peroxidise labelled rabbit
anti-chicken IgG (Millipore, Temecula, California, USA), 100 ml/
well were added and incubated for 1 h at RT. After washing, the
substrate solution (100 mg/ml of tetramethylbenzidine substrate
(TMB) (Sigma, St Louis, MO, USA) in citrate buffer (pH 8),
containing hydrogen peroxide (100 ml of 0.6% H2O2), was added
(100 ml/well) and the plates were incubated for 10–15 min. The
colour reaction was stopped by adding 1 M sulphuric acid, and
OD450 was determined.
Optimization of Synthetic Peptide ELISA
Both M2e-23 and M2e-18 synthetic peptides were used in
ELISA as coating antigens. Briefly, 1 mg of each lyophilized
peptide was dissolved in 1 ml of sterile distilled water, and 2-fold
serial dilutions of 160 to 0.31 mg/ml of the peptide made in 0.1 M
carbonate–bicarbonate buffer, pH 9.6. Diluted peptides were used
to coat the 96-well flat bottom microtiter plates (Maxisorp,
NUNC). All steps, including the checkerboard titration, were
performed as described for M2e-MBP ELISA.
In both M2e peptides and M2e-MBP ELISAs, for each serum
sample, 4 wells were used: 2 wells were coated by the antigen
whereas 2 wells were not coated with any antigen and served as an
internal control for each serum. For each serum, the mean OD450
of antigen negative wells subtracted from the mean OD450 of
antigen positive wells and the obtained OD450 was termed as
‘‘corrected OD450 value’’. A serum was considered positive when
its corrected OD450 value was greater than the mean corrected
OD450 for negative sera plus 2 times standard deviation (cut-off
value).
Challenged Experiment: Simulation the Efficiency of the
Presented Recombinant M2e-based ELISA Method in
Comparison to the Common HA-based Method (HI Titre)
for DIVA Test
The aim of this experiment was to simulate the condition and
measure the sensitivity of the presented recombinant M2e-based
ELISA method when the vaccinated chickens infect with the live
virus. In addition, the efficiency of our method was compared with
the HI titre (common HA-based method).
Table 1. Reference (Avian Influenza Virus) AIV antisera used
in the study.
Avian influenza strain used for
immunization Type HI Titre log2
1
1 A/Chicken/Scotland/1959 H5N1 72
2 A/Ostrich/Denmark/72420/1996 H5N2 7
3 A/Turkey/Wisconsin/1/1966 H9N2 9
4 A/Tky/England/96 H3N2 7
5 A/Duck/Alberta/35/76 H1N1 9
6 A/African starling/England-Q/983/79 H7N1 8
7 A/Duck/England/1/1956 H11N6 9
8 A/Duck/Ukraine/1/1963 H3N8 6
9 A/Duck/Germany/1215/1973 H2N3 6
10 A/Turkey/England/647/77 H7N7 7
11 A/Ck/Viet Nam/8/2004 H5N1 ND3
12 A/Chicken/Konawi Selatan/8/2004 H5N1 H5N1 ND3
1Homologous HI Titre.
2Source of challenged and vaccinated antibodies.
3ND: HI Titre not detected.
doi:10.1371/journal.pone.0056801.t001
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Chicken sera resulting from an experimental vaccination/
challenge experiment were provided by the Indonesian Research
Centre for Veterinary Science, Bogor. Twenty chicks, 21 days old,
were sourced from non-vaccinated AI free broiler farm and
divided into 2 groups, each with 10 chicks. Chickens in the first
group were vaccinated with a single dose of an experimental
inactivated vaccine prepared from A/Ck/West Java/Pwt-Wij/
2006 strain of H5N1 (Accession No; EU124148). Chickens in the
second group were remained unvaccinated and kept in the same
condition but in a separate isolation units.
Three weeks after vaccination, all birds were tested for HI
antibody titres using the homologous HA antigen (A/Ck/West
Java/Pwt-Wij). Then, chicks in both groups were transferred to
isolation units, housed within the PC3 facility. After that, chicks in
the first group were challenged with 106 ELD50 in 0.1 ml via
intranasal inoculation with A/Ck/West Java/Pwt-Wij/2006.
Chicks in the second group were remained unvaccinated and
unchallenged. Two weeks after challenge, sera were collected from
all chicks in both groups and tested individually for HI antibody
titres using the HA antigen A/Ck/West Java/Pwt-Wij and also
M2e ELISA, to compare the ability of these methods in
monitoring the infection of vaccinated chickens. In addition, in
first group, the responses of M2e ELISA and HI Titre methods to
challenged infection were compared by T-test statistics using
Minitab 16 package (www.minitab.com).
Large Scale DIVA Test Using the Recombinant M2e-based
ELISA
The goal of this experiment was to evaluate the robustness of
the recombinant M2e ELISA method in the field scale. Three test
groups were examined, including (a) Negative group (non-infected
and non-vaccinated): 204 field sera from commercial broiler and
layer flocks in Australia and Indonesia which were confirmed to be
AIV antibody free by an IDEXX AIV antibody test (IDEXX
Laboratories, Inc) and were obtained from the diagnostic
laboratory, School of Veterinary Science, the University of
Melbourne, (b) Vaccinated group, sera (334 in total) were collected
from vaccinated commercial broiler and layer flocks in Indonesia,
and (c) Infected group: 56 sera were collected from infected
chickens from different farms in Indonesia.
Corrected ODs (450 nm) of each serum in recombinant M2e
ELISA were recorded individually and compared between
different test groups. Furthermore, analysis of variance mean
comparisons by Tukey test was performed to evaluate the ability of
M2e-based ELISA in distinguishing the infected sera from the
vaccinated and non-vaccinated sera (Table 2).
ELISA Cut-off Values
The cut-off values for the ELISAs were calculated from the
results of sera of H5N1 infected (standard and challenge
experiment groups) and vaccinated chickens (field and challenge
experiment groups) using the two-graph receiver operating
characteristic (TG-ROC) analysis [26,27].
Ethics Statement
All animal experiments were performed at the Indonesian
Research Centre for Veterinary Science, Bogor, Indonesia. The
study proposal was approved by the institutional Research
Committee.
The animals were managed by a veterinarian who specializes in
animal studies based on the guidelines of the National Health and
Medical Research Council of Australia. All birds were bleed via
brachial vein during the experiment and cardiac puncture at the
terminal step just after CO2 euthanization.
Results
M2e Consensus Sequence Used for Expression
In total, 64 nucleotide sequences of the M2e gene of deposited
Indonesian H5N1 strains in GeneBank (with human and avian
origin) were aligned. The obtained consensus M2e sequence from
this alignment was that of A/Indonesia/CDC540/2006 H5N1
strain since it shared the highest identity matrix,.95%, with other
Indonesian H5N1 strains. The length of sequence was 72
nucleotides and also had the highest hydrophilicity profile among
the compared M2e amino acid sequences (result not shown). The
hydrophilicity is one of the factors that influence both antigenicity
and antibody binding avidity. High hydrophilicity increases the
chance of detection of the specific antibodies. We optimized the
codons of this 72 bp long M2e sequence, cloned and expressed in
E. coli, BL21 cells.
Characterization of the Recombinant M2e-MBP Protein
Maximum expression level of M2e-MBP was detected at 3 h
after induction. SDS-PAGE analysis of the purified M2e-MBP
protein demonstrated the presence of two 45.1 and 42.5 kd bands
(Figure 1A). The 45.1 kd band corresponded to the expected
recombinant protein containing 2.6 kd M2e and 42.5 kd MBP,
whereas 42.5 kd band corresponded to the MBP alone. Therefore
it is likely to be truncated M2e-MBP protein.
Confirmation of the Expressed Recombinant Protein with
Western Blot
The purified M2e-MBP fusion protein reacted in Western blot
with AIV chicken sera that included antisera to live H5N1 (A/
Chicken/Scotland/1959 and A/Ck/Viet Nam/8/2004), live
H5N2 (A/Ostrich/Denmark/72420/1996), and live H9N2 (A/
Turkey/Wisconsin/1/1966) (Figure 1B). H5N1, as well as H5N2
and H9N9 antisera reacted with 45.1 kd band which contains
M2e. None of these sera reacted with MBP alone, indicating that
the recognition of 45.1 kd band is due to the presence of M2e and
not MBP (Figure 1B). Antisera to inactivated H5N1 (vaccine) did
not bind to the M2e-MBP indicating that immunisation with
inactivated virus did not give rise to the M2e antibodies,
documenting the robustness of the presented method.
Pool of field sera from AIV free, non-vaccinated chicks, did not
react with the M2e-MBP protein in Western blot (Figure 1B).
However, a weak reaction was observed with alone MBP protein
(Figure 1C, lane 6), likely due to the higher concentration of MBP
when MBP used alone in Western Blotting.
Optimization of Recombinant M2e-MBP and Synthetic
M2e Peptide ELISA
Since Western blot analysis confirmed that the recombinant
M2e-MBP fusion protein is antigenic and can differentiate live
infected from vaccinated antisera, feasibility of using this antigen
in ELISA was assessed. In addition, the synthetic M2e-18 peptide
ELISA was used for comparison as was previously shown to be
able to discriminate between infected and vaccinated chicks
[22,28]. Initially, both peptide and M2e-MBP ELISA were
optimized for the amount of coating antigen and dilution of
antisera. For M2e-MBP as coating antigen and antisera to live
H5N1, the lowest background and maximum absorbance were
determined to be at approximately 25 mg/ml for M2e-MBP
antigen and 10 mg/ml for M2e-18 peptide (Figure 2). The highest
M2e ELISA as a Tool for DIVA Test
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ratios of OD450 for H5N1 live and killed antisera, with minimum
non-specific reaction, was obtained at sera dilution of 1:100 and
consequently this dilution was used for all test sera in ELISA.
Comparison of Recombinant M2e-MBP and Synthetic
M2e Peptide ELISA in Detection of Live AIV Exposure
Reactivity of sera from chicks immunized with 11 different
subtypes of AIV, with HI titres between 6 to 9 (log 2 base) were
compared in recombinant M2e-MBP and synthetic M2e peptide
ELISA (Figure 3). As it can be inferred from Figure 3, a
considerable agreement exists between the recombinant M2e-
MBP and synthetic M2e peptide ELISA for all sera. The highest
difference was observed for H3N2 antiserum, where its reaction
with the M2e-MBP protein was lower in comparison to its reaction
with the M2e synthetic peptide. One of the possible reasons of this
difference (in the case of H3N2) is the lower signal to noise ratio
for M2e-MBP ELISA comparing to synthetic peptide ELISA. It
should be noted that higher signal of synthetic peptide ELISA is
related to the higher purity of synthetic peptide.
As presented in Figure 3, two live H5N1 strains, Scotland and
Vietnam, strongly reacted with recombinant M2e-MBP and
synthetic M2e peptide, whereas sera to inactivated H5N1 did
not react. This clearly demonstrates the high performance of M2e
in DIVA test for distinguishing vaccinated from infected chickens.
Significant positive Pearson correlation (p= 0.05, 67%) was
observed between M2e-MBP and synthetic M2e peptide which
highlights the possibility of employing inexpensive recombinant
M2e-MBP instead of synthetic M2e protein.
Of interest was that antisera to live AIV of subtypes other than
H5N1, including H11N6, H7N7, H1N1, H7N1, H2N3, H9N2,
H3N8 and H5N2, all reacted in ELISA with both M2e-MBP and
M2e peptide while M2e sequence was derived from H5N1 strain.
In line with this finding, De Filette et al., (2008) showed that
vaccines based on M2e can induce broad-spectrum immunity
against influenza in mice and is the best candidate for M2e-based
universal influenza vaccine [16]. Similarly, broad protection
Table 2. Mean comparisons and analysis of variance of recombinant M2e-MBP ELISA results on sera from challenged, negative,
and vaccinated tested groups.
Mean comparison
Test group Mean Standard Deviation
Mean comparison by Tukey method at 99%
Confidence level1
Infected 0.9269 0.2711 A
Vaccinated 0.2124 0.1981 B
Negative 0.1955 0.0108 B
Analysis of Variance
Source of variation Degree of freedom Mean squares F-value P-value2
Test group 2 13.197 355.44 0.0001
Error 591 0.037
1Means that do not share a letter are significantly different.
2Highly significant.
doi:10.1371/journal.pone.0056801.t002
Figure 1. SDS-PAGE and Western blot results of M2e-MBP recombinant protein. A) Purified recombinant M2e-MBP (lane 1) and MBP (lane
2) proteins and pre-stained molecular marker (M) analysed by SDS–PAGE (12.5%) and stained using Coomassie Brilliant Blue. (B & C) Western blot
analysis of purified M2e-MBP (1B) and MBP (1C) with reference AIV antisera to: (1) live A/Chicken/Scotland/1959 (H5N1); (2) inactivated H5N1; (3) live
A/Ck/Viet Nam/8/2004 (H5N1); (4) live A/Turkey/Wisconsin/1/1966 (H9N2); (5) live A/Ostrich/Denmark/72420/1996 (H5N2); (6)sera from commercial
non-vaccinated non-infected; (7) SPF chicken sera.
doi:10.1371/journal.pone.0056801.g001
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against different H1 swine influenza virus was achieved by
application of swine influenza M2 protein [18].
High Sensitivity of Recombinant M2e-MBP ELISA for DVIA
Test, Superiority Over the Common HA-based Method
(HI Titre)
Figure 4 compares the response of HI titre and recombinant
M2e ELISA in monitoring the infection in vaccinated chickens
with live virus. HI titre could not distinguish the further infection
of vaccinated chicken with live virus (A/Ck/West Java/Pwt-Wij/
2006) (Figure 4A). In contrast, while vaccinated and non-
vaccinated chickens have the similar ELISA OD before infection,
the level of ELISA OD sharply increased by more than 8 times
(from 0.14 to 1.2) (Figure 4B). The cut-off point for M2e-MBP
ELISA was 0.58. T-test statistically confirmed the highly
significant response of M2e ELISA test to live virus infection at
p = 0.00001(data not shown). This result confirms high efficiency
of the presented recombinant M2e-based ELISA method in DIVA
test and its superiority over the common HA-based method.
Evaluation of M2e-MBP and M2e Peptide ELISA with Field
Serum Samples (Large Scale DIVA Test)
Specificity of M2e-MBP and M2e peptide ELISA were also
evaluated using chicken sera from non-vaccinated and vaccinated
Figure 2. Optimization of recombinant M2e-MBP protein (A) and M2e-18 synthetic peptide (B) as coating antigens in ELISA. Anti-
H5N1 live, anti-H5N1 killed, SPF and sera from non-vaccinated commercial chickens (field sera) were diluted 1:100 and incubated with M2e-MBP or
M2e-18 used for coating at various concentration. Reactivity of sera with coating antigen was detected by rabbit anti-chicken IgG-HRP. Absorbance
(OD) of conjugate control (CC) was measured for each plate.
doi:10.1371/journal.pone.0056801.g002
Figure 3. Comparison of recombinant M2e-MBP protein and synthetic M2e peptide ELISA for detection of M2e antibodies in
reference sera. All sera were generated against live AIV of indicated subtypes, except for H5N2 killed virus.
doi:10.1371/journal.pone.0056801.g003
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commercial layers and non-vaccinated broilers as described in
materials and methods. Sera from non-vaccinated layers were
negative in both M2e-MBP and M2e peptide ELISA, except for 6
sera that were positive in M2e-MBP ELISA with the OD450 value
greater than 0.58 (false positive rate = 2.9%) (Figure 5). Western
blot analysis of these sera revealed that they had reacted with the
MBP contained in the fusion protein and but not against M2e
(data not shown). In vaccinated group, 19 out of 334 were also
positive in M2e-MBP ELISA (false positive is 5.6%) (Figure 5).
As it can be inferred from Figure 5, the presented M2e-MBP
ELISA is highly efficient in differentiation of infected from non-
infected (negative) and vaccinated groups in field level (large scale).
Analysis of variance revealed a highly significant difference
between infected group in comparison to non-infected and
vaccinated groups with respect to ELISA OD values (p = 0.0001)
(Table 2).
Discussion
Vaccination is the method of choice to control AIV in poultry
industry in many countries. Fast, efficient, and inexpensive DIVA
test has a vital role in the success of this strategy. To address this
issue, we expressed the M2e peptide as a recombinant M2e-MBP
protein in E.coli. After purification by affinity chromatography, its
specificity to detect M2e antibodies was confirmed by both
Western blotting and ELISA. Synthetic M2e peptide has been
Figure 4. Comparison of HI titres and M2e-MBP ELISA OD in chicks vaccinated and then challenged by A/Ck/West Java/Pwt-Wij/
2006.
doi:10.1371/journal.pone.0056801.g004
Figure 5. Large scale (field) application of recombinant M2e-MBP ELISA results on sera from infected (challenged), non-vaccinated,
and vaccinated groups. Cut-off value (0.58) calculated as mean corrected OD for negative samples plus 2 standard deviations (0.364).
doi:10.1371/journal.pone.0056801.g005
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used previously in chickens [22]. Application of M2e as
recombinant protein, instead of as a peptide, has dual benefits.
Recombinant M2e provides a continuous access to an inexpensive
reagent for a large scale screening. The second benefit of
recombinant M2e protein is the opportunity of demonstrating
the M2e-based assay specificity by another method, in this case
Western blotting, which is not possible when M2e is used as a
peptide.
The expressed recombinant M2e-MBP protein had an expected
size of 45.1 kd corresponded to 2.6 kd M2e and 42.5 kd MBP.
Another minor protein of 42.5 kd corresponding to truncated
M2e-MBP, was also co-purified with M2e-MBP and was not
possible to remove from the preparation of M2e-MBP by
additional purification.
Western blotting recognised the M2e-MBP protein of 45.1 kd
length only by antisera to live AIV whereas antisera to inactivated
H5N1 did not react with the M2e-MBP. This reaction in Western
blotting was demonstrated to be due to M2e only and not due to
MBP.
The comparison of M2e-MBP and peptide ELISA using
reference sera indicted that M2e-MBP antigen was equally
capable of detecting M2e positive sera without any significant
background noise, or non-specific reaction. All sera that were
positive by peptide ELISA were also positive in M2e-MBP ELISA,
and in full agreement with the results obtained by M2e-MBP
based Western blotting, indicated that M2e expressed as fusion
M2eMBP protein is antigenically functional. The recombinant
M2e-MBP was expressed in large quantities and allowed sera to be
tested for M2e antibodies at a relatively high dilution of 1/100.
The signal to noise ratio in ELISA was significantly different and
allowed clear differentiation of M2e positive reference sera.
UP to now, M2e peptide has been expressed in Salmonella, Pichia
pastoris, plants and viruses for the purpose of studying the
protective immunity induced by the M2e [29,30,31]. Only in
one study the M2e was expressed as GST fusion protein in E. coli
and used to analyse the antibody response to the swine influenza
virus M2e [32]. Application of efficient and high productive E.coli
platform in this study provides the opportunity of production of a
large amount of recombinant M2e protein in a short period of
time. Further dilution of the producd protein (1/100 dilution,
because of high ratio in this study) as a result of high recombinant
protein yield in E.coli platform significantly decreases the non-
specific resulting in more accurate DIVA test.
The comparison of the results of M2e-MBP ELISA and HI
(HA-based) tests demonstrated the excellent ability of M2e-MBP
antigen to discriminate between antibodies produced against live
virus challenge and killed virus vaccination for DIVA serological
test. M2e-MBP ELISA was highly sensitive to live virus infection
as the ELISA OD of vaccinated chickens greatly increased by
more than 8 time when vaccinated chickens were infected with the
live AIV virus (Figure 5).
Furthermore, the robustness of the method reinforced by large
scale M2e-MBP ELISA in differentiation of infected chickens from
non-infected and vaccinated chickens (Figure 5). With negative
field sera the background noises in M2e MBP ELISA were
however higher. In order to reduce the of biases of non-specific
binding, each serum sample was tested in duplicate in the presence
and absence of M2e MBP antigen and background noise
subtracted from OD obtained on M2e MBP. This non-specific
binding of a percentage of field sera is largely independent of the
antigen used for coating as shown by others [23] and also was
occurred in M2e peptide ELISA.
The newly designed M2e-MBP ELISA system using as a DIVA
tool has some limitations in its application in old chicken and the
serum samples that were haemolysed or lipemic. Some of the field
serum samples from old flocks (older than 44 weeks) had different
degrees of non-specific reactions with M2e-MBP antigen. Western
blot analysis using MBP purified fusion protein revealed that these
samples had different reactivity just with MBP fusion protein but
not with M2e.
Also some of the serum samples from layer or free range chicks
had non-specific reactions to MBP fusion protein and/or just the
ELISA plates alone. To overcome these problems using fresh, non-
haemolysed and preferably non-lipemic serum samples would be
an advantageous. Where it is necessary the results can be
confirmed by Western blotting or subtracting the MBP value
from the whole antigen. Second critical item in reliability of the
M2e-MBP ELISA is purity of the antigen, in some cases during
purification procedure of the antigen some of E.coli proteins could
contaminate purified protein, and these residues will react with
chicken antibodies, increasing the background of the tested
samples in ELISA. Regarding some non-specific binding encoun-
tered in indirect M2e-MBP ELISA, being either due to the nature
of the antigen or the properties of the chicken serum, we suggest
that the use of a competitive or blocking ELISA for the detection
of M2e antibodies might be an approach to reduce non-specific
reactions with chicken sera.
H5N1-originated recombinant M2e-MBP protein or synthetic
M2e peptide reacts with a wide range of other AIV strains
antibodies such as H5N2, H9N2, H7N7, H11N6, etc. While the
major surface influenza glycoproteins, HA and NA undergo major
antigenic changes resulting in short-time effectiveness of available
vaccines, the extracellular domain of matrix protein 2 (M2e) is
strongly invariable and conserved. Therefore, vaccines based on
extracellular domain of M2e are capable in inducing broad-
spectrum immunity and inhibit virus replication up to 90–100%
protection in mice and heterosubtypic immunity in pigs [16,18]. In
fact, the recent concept of a ‘‘universal influenza vaccine’’ relies on
the conserved ectodomain of the influenza A protein [16,18].
In addition to the above-mentioned advantages, extracellular
domain of M2e opens a new vista in avian influenza management
via DIVA test. Hydrophilic structure of M2e as well as its
invariability and broad-spectrum reactivity show that M2e is an
appropriate candidate for both vaccine production and DIVA test.
The high performance of M2e subunit for DIVA test can be
explained by considerable lower number of M2 molecules per
virion (20–60) comparing to HA and NA. Due to larger amount of
HA molecule per virion. HA can induce a very strong immune
response in both vaccinate (killed virus) and infected chickens. In
contrast, the amount of M2e subunit in vaccine is very low, and
immune response can be detected after live virus infection as
presented in Figure 4.
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